{"schema_version":"secwatch.filing_event.v1","accession":"0001479681-25-000008","form_type":"8-K","ticker":"NUTX","cik":"0001479681","company_name":"Nutex Health Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.744497+00:00","generated_at":"2026-05-24T01:42:10.287901+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nutex Health reports FY 2024 net income of $52.2M vs loss of $45.8M in 2023; revenue up 93.8% to $479.9M","bullets":["FY 2024 total revenue $479.9M (+93.8% YoY); net income $52.2M vs net loss $45.8M in 2023.","Diluted EPS $9.71 vs $(10.39); Adjusted EBITDA $123.7M up 1,045% from $10.8M.","Arbitration process added $169.7M more revenue in 2024 than 2023; drove 73.1% of revenue growth.","Q4 2024 revenue $257.6M (+270% YoY); operating income $114.2M vs operating loss $26.1M.","Cash from ops $23.2M; total assets $655.3M; long-term debt $22.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001479681-25-000008","json":"https://secwatch.observer/filing/0001479681-25-000008.json","markdown":"https://secwatch.observer/filing/0001479681-25-000008.md","text":"https://secwatch.observer/filing/0001479681-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479681/000147968125000008/0001479681-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479681/000147968125000008/nutx-20250331x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:42:10.287901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}